Both in Pharmaceuticals
Arrowhead Research vs Alkermes
Over the past year ARWR returned +51.2% and ALKS returned +50.3%; their daily moves had a correlation of 0.27.
ARWR +51.2% ALKS +50.3%Growth of $1, one year, split-adjusted
| Metric | ARWR | ALKS |
|---|---|---|
| Price | $59.90 | $45.34 |
| Market cap | $8.46B | $7.61B |
| Today | −0.98% | −0.07% |
| 1 month | −7.5% | +11.8% |
| 6 months | −19.9% | +35.8% |
| Year to date | −9.8% | +62.0% |
| 1 year | +48.7% | +44.2% |
| Revenue growth (YoY) | +171.0% | +27.0% |
| Gross margin | 100.0% | 80.2% |
| Net margin | −258.2% | 0.1% |
| P/E (TTM) | — | 115.0× |
| Price / sales | 12.6× | 4.6× |
| Net cash | $737.9M | -$846.5M |
| Dividend yield | — | — |
| Volatility (60d) | 45.6% | 31.7% |
| Short % of float | 8.1% | 11.5% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).